Addressing Challenges in Prescribing Afrezza to Patients with Respiratory Conditions

Afrezza (insulin human) inhalation powder is a rapid-acting inhaled insulin approved for the management of hyperglycemia in adults with diabetes. Its ultra-fast pharmacokinetic profile, with peak action reached within 12–15 minutes, offers a unique option for prandial glucose control. However, because Afrezza is administered via the pulmonary route, prescribing it to patients who have comorbid respiratory conditions carries distinct clinical challenges. Healthcare providers must carefully weigh the potential benefits against respiratory risks, perform thorough baseline assessments, and implement tailored monitoring plans. This expanded guide covers the evidence-based considerations, contraindications, evaluation protocols, patient education strategies, and alternative options for managing diabetes in patients with respiratory disease.

Understanding the Risks: Pulmonary Effects of Inhaled Insulin

Inhaled insulin delivers medication directly to the alveolar epithelium, bypassing the gastrointestinal tract and first-pass metabolism. While this route enables rapid absorption, it also exposes the lungs to a foreign protein. For individuals with underlying respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), or interstitial lung disease, inhaled insulin can provoke bronchospasm, decline in forced expiratory volume in one second (FEV1), or increased cough.

Acute and Chronic Pulmonary Adverse Events

Clinical trials and post‑marketing surveillance have documented the following risks:

Acute bronchospasm – Especially in patients with asthma or reactive airway disease. In controlled studies, Afrezza was associated with a higher incidence of cough (up to 30%) and transient reductions in FEV1 of 40–80 mL compared to subcutaneous insulin.
Decline in lung function – Long‑term use may lead to a small, non‑progressive decline in FEV1 during the first six months, which then stabilizes. Patients with pre‑existing COPD or asthma may experience a more pronounced drop.
Worsening of baseline respiratory symptoms – Patients with active infections, mucus hypersecretion, or airflow obstruction are at greater risk for exacerbation.

Because of these risks, the U.S. Food and Drug Administration (FDA) prescribing information includes a boxed warning for acute bronchospasm and contraindicates Afrezza in patients with asthma or COPD. It also mandates spirometry testing before initiation and periodically during therapy.

Mechanisms of Pulmonary Vulnerability

In patients with asthma, hyperresponsive airways constrict in reaction to inhaled particles; the insulin powder can act as an irritant. In COPD, chronic inflammation and structural changes (emphysema, mucus plugging) reduce the surface area available for absorption and increase the likelihood of retained drug particles triggering local inflammation. Additionally, patients with respiratory conditions often have impaired mucociliary clearance, leading to prolonged drug contact with airway epithelium.

Contraindications and Patient Exclusions

Before considering Afrezza, clinicians must identify absolute contraindications and high‑risk candidates:

Absolute contraindications: Current asthma (controlled or uncontrolled), COPD (including chronic bronchitis and emphysema).
Relative contraindications: History of lung disease (e.g., interstitial lung disease, pulmonary fibrosis), recurrent pneumonia, active respiratory infection, recent hospitalization for respiratory distress.
Cautions: Current smokers (smoking increases inhaled insulin absorption unpredictably and alters lung function), patients using other inhaled medications (such as bronchodilators or corticosteroids) – timing and technique interactions may affect efficacy and safety.

Note: Afrezza has not been studied in patients with asthma or COPD, so risks are extrapolated from trials that excluded these populations. ClinicalTrials.gov listings reveal ongoing studies exploring safety in broader populations, but current evidence strongly supports avoidance in these groups.

Assessing Patient Suitability: A Stepwise Clinical Approach

For patients without overt respiratory disease but who may have subclinical lung impairment (e.g., remote history of bronchitis, occasional wheezing), a structured assessment is essential before prescribing Afrezza.

Step 1 – Detailed Medical History

Focus on:

Past diagnosis of asthma, COPD, bronchitis, reactive airway disease, or allergies
Hospitalizations or emergency visits for breathing problems
Chronic cough, sputum production, or shortness of breath
Tobacco use (current or former) and pack-year history
Occupational or environmental exposures (e.g., dust, chemical fumes)
Current medications, especially inhaled corticosteroids, beta-agonists, or anticholinergics

Step 2 – Physical Examination

A respiratory exam should include:

Auscultation for wheezes, rales, or diminished breath sounds
Assessment of accessory muscle use or prolonged expiratory phase
Measurement of oxygen saturation by pulse oximetry

Step 3 – Objective Lung Function Testing (Spirometry)

The FDA label requires that spirometry be performed:

Before initiation of Afrezza
After 6 months of therapy
Annually thereafter
If the patient develops new or worsening respiratory symptoms

Key parameters: FEV1, forced vital capacity (FVC), and FEV1/FVC ratio. Patients with an FEV1 less than 80% of predicted or an FEV1/FVC less than 0.7 are at higher risk and should not be started on Afrezza. Clinicians may consider consultation with a pulmonologist if borderline values are found.

Step 4 – Evaluate Current Respiratory Status

Do not initiate Afrezza during an active respiratory infection (e.g., acute bronchitis, pneumonia, COVID‑19). Wait until the patient is symptom‑free and spirometry returns to baseline (at least 4 weeks after clinical resolution). Patients with frequent exacerbations of asthma or COPD (≥2 per year) should be considered unsuitable.

Key Evaluation Steps: Summarized Checklist

To operationalize the assessment, clinicians can use the following checklist during the pre‑prescribing visit:

☐ Confirm patient does NOT have asthma, COPD, or other chronic lung disease (verify with records)
☐ Obtain complete smoking history; recommend smoking cessation if applicable
☐ Perform spirometry: FEV1 ≥ 80% predicted, FEV1/FVC ≥ 0.7
☐ Rule out acute respiratory infection (no cough, fever, sputum within past 4 weeks)
☐ Review concomitant inhaled medications – plan for timing (use bronchodilator before Afrezza if both needed)
☐ Educate on proper inhaler technique (use a standardised teach‑back method)
☐ Schedule follow‑up spirometry and symptom check at 3–6 months
☐ Provide written action plan for acute respiratory symptoms (when to stop Afrezza and seek care)

Monitoring and Patient Education: Ongoing Safety Surveillance

Once Afrezza is prescribed, the clinician and care team shoulder the responsibility of continuous monitoring. This is particularly important because pulmonary adverse effects can develop even in patients who initially pass screening.

Routine Monitoring Schedule

Baseline: Spirometry, respiratory symptom questionnaire, HbA1c, fasting glucose.

Month 3: Telephone or virtual check‑in for cough, dyspnea, wheeze; review inhaler technique.

Month 6: Spirometry (FEV1, FVC) plus symptom assessment. If FEV1 declines >10% from baseline, discuss discontinuation.

Annually: Repeat spirometry and consider referral to pulmonology if any downward trend.

As needed: Any report of worsening cough, chest tightness, or shortness of breath triggers an immediate clinic visit with spirometry.

Patient Education Points

Proper inhaler technique: Afrezza uses a single‑use cartridge and a breath‑powered inhaler. Patients should be taught to exhale fully (but not into the mouthpiece), then inhale deeply and steadily through the device, hold breath for 5 seconds, then exhale normally. Incorrect technique reduces drug delivery and increases risk of cough.
Recognizing warning signs: Counsel patients to stop using Afrezza and call their healthcare provider if they experience new or worsening cough, wheezing, chest tightness, shortness of breath, or hemoptysis.
Avoiding smoking: Smoking changes lung function and increases insulin absorption variability. Smoking cessation is strongly recommended before and during Afrezza therapy.
Medication interactions: If using a bronchodilator inhaler (e.g., albuterol), advise to take the bronchodilator first, wait 5–10 minutes, then use Afrezza. This sequence reduces bronchospasm risk and improves drug deposition.
Hypoglycemia awareness: Inhaled insulin may cause hypoglycemia; the patient should be taught to recognize symptoms and have rapid‑acting glucose available. Because Afrezza peaks quickly and clears quickly, post‑prandial hypoglycemia can occur within 30–60 minutes.

Alternative Insulin Delivery Options for High‑Risk Patients

When a patient with diabetes and a respiratory condition is deemed ineligible for Afrezza, clinicians should not feel limited. Multiple alternative therapies exist, and collaborative management ensures glycemic control without added pulmonary risk.

Subcutaneous Prandial Insulins

Rapid‑acting analogues (lispro, aspart, glulisine) are the standard prandial insulins. They can be injected with insulin pens or syringes, and newer ultra‑rapid formulations (e.g., faster‑acting insulin aspart) approach the absorption speed of Afrezza without pulmonary exposure.

Inhaled insulin alternatives – None are currently approved other than Afrezza. However, some patients may be candidate for continuous subcutaneous insulin infusion (CSII) for more flexible dosing.

Non‑Insulin Injectable Therapies

For type 2 diabetes, options such as glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs, e.g., liraglutide, semaglutide) or dual agonists (tirzepatide) can be used as alternatives to prandial insulin, reducing the need for bolus insulin exposure. Patients with respiratory conditions should still be monitored for gastrointestinal side effects and, in rare cases, aspiration pneumonia, but the pulmonary risk is minimal.

Collaborative Care – Multidisciplinary Team

Managing diabetes in a patient with asthma or COPD requires input from:

Pulmonologist – Regular lung function assessments, optimisation of respiratory therapy
Endocrinologist – Insulin dose titration, especially if using inhaled insulin in borderline cases
Pharmacist – Review of drug interactions and inhaler technique
Diabetes educator – Education on monitoring glucose, recognising hypoglycemia, and lifestyle modifications

Special Populations and Considerations

Pediatric Patients

Afrezza is not approved for persons younger than 18 years. Children with diabetes and asthma present an even higher risk due to developing lungs and more frequent respiratory infections. In pediatric populations, subcutaneous insulins remain the standard.

Elderly Patients

Older adults often have age‑related decline in lung function and increased rates of COPD and congestive heart failure. Their ability to master inhaler technique may be reduced. Therefore, Afrezza should be used sparingly in this population, and only after rigorous assessment.

Patients with COVID‑19 History

Post‑COVID‑19 patients may have residual pulmonary impairment (e.g., reduced diffusion capacity, fibrosis). These individuals should not be prescribed Afrezza until lung function has been fully evaluated and has returned to predisease baseline, which may take months.

Evidence from Clinical Studies

Key clinical trials that inform Afrezza’s safety profile include:

Study 1 (Phase 3 safety trial): In patients with type 1 and type 2 diabetes without underlying lung disease, Afrezza showed a mean FEV1 decline of 40 mL at 24 weeks compared to subcutaneous insulin, which stabilised at 52 weeks. Cough was reported by 25–30% of patients. (Source: Rosenstock et al., 2015, Diabetes Care)
Study 2 (COPD exclusion): Patients with COPD were excluded from pivotal trials. In a small pilot study of patients with mild COPD, inhaled insulin caused a 100–150 mL decline in FEV1, leading to discontinuation in several participants.
Long‑term extension study: Over two years, patients without respiratory disease maintained stable lung function after the initial 6‑month dip, with no continued decline.

These data underscore the importance of patient selection. For those without respiratory conditions, Afrezza is generally safe with appropriate monitoring. For those with known lung disease, the risks outweigh the benefits.

Practical Decision‑Making Algorithm

To streamline the clinical decision, consider the following algorithm:

Does the patient have a diagnosis of asthma, COPD, or any chronic lung disease? → No → Proceed to step 2. → Yes → Contraindicated; consider alternative insulin.
Does the patient smoke or have a history of smoking >10 pack‑years? → No → Proceed to step 3. → Yes → Perform spirometry; if FEV1 ≥ 80% and no symptoms, cautious initiation with close monitoring; otherwise, avoid.
Is spirometry normal (FEV1 ≥ 80% predicted, FEV1/FVC ≥ 0.7)? → Yes → Initiate Afrezza with baseline education and monitoring plan. → No → Avoid Afrezza; refer to pulmonary specialist.
Are there current respiratory symptoms or infection? → No → Initiate. → Yes → Defer initiation until symptom‑free and spirometry stable.

Conclusion and Clinical Pearls

Prescribing Afrezza to patients with respiratory conditions is a high‑stakes decision that should not be taken lightly. The rapid‑acting profile of Afrezza offers distinct advantages in glycemic control, but only when pulmonary safety is assured. Key takeaways for clinicians:

Always screen for undiagnosed asthma or COPD – a negative history is not sufficient; spirometry should be performed.
Contraindicate Afrezza in any patient with asthma or COPD, regardless of severity.
Educate patients rigorously on technique and symptom recognition; misuse can lead to adverse outcomes.
Maintain a low threshold for discontinuing Afrezza if new respiratory symptoms appear.
Collaborate with a pulmonologist and endocrinologist for optimal outcomes.

By adhering to these principles, clinicians can harness the benefits of Afrezza in appropriate candidates while avoiding preventable harm in the respiratory‑compromised population. The ultimate goal remains safe, individualised diabetes management that respects both metabolic and pulmonary health.

For further reading, refer to the full Prescribing Information for Afrezza and the American Diabetes Association Standards of Care.

Addressing Challenges in Prescribing Afrezza to Patients with Respiratory Conditions

Table of Contents